Latest & greatest articles for fluticasone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on fluticasone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on fluticasone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for fluticasone

61. Cost-effectiveness of salmeterol, fluticasone, and combination therapy for COPD

Cost-effectiveness of salmeterol, fluticasone, and combination therapy for COPD Cost-effectiveness of salmeterol, fluticasone, and combination therapy for COPD Cost-effectiveness of salmeterol, fluticasone, and combination therapy for COPD Oba Y Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment (...) on the reliability of the study and the conclusions drawn. CRD summary The aim was to assess whether maintenance inhaled medication was cost-effective for patients with moderate-to-severe chronic obstructive pulmonary disease. The author concluded that, at willingness-to-pay thresholds over 52,800 US dollars per quality-adjusted life-year, combined fluticasone and salmeterol propionate therapy was most cost-effective, below this threshold no maintenance therapy, with bronchodilator use as needed, was most cost

2009 NHS Economic Evaluation Database.

62. Cost-effectiveness of fluticasone propionate/salmeterol (500/50 micrograms) in the treatment of COPD Full Text available with Trip Pro

Cost-effectiveness of fluticasone propionate/salmeterol (500/50 micrograms) in the treatment of COPD Cost-effectiveness of fluticasone propionate/salmeterol (500/50 micrograms) in the treatment of COPD Cost-effectiveness of fluticasone propionate/salmeterol (500/50 micrograms) in the treatment of COPD Earnshaw SR, Wilson MR, Dalal AA, Chambers MG, Jhingran P, Stanford R, Mapel DW Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED (...) . Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to estimate the cost-effectiveness of the combination of fluticasone propionate and salmeterol compared with no maintenance treatment in chronic obstructive pulmonary disease. The authors concluded that both the combination and salmeterol alone were cost-effective compared

2009 NHS Economic Evaluation Database.

63. Salmeterol and fluticasone propionate did not reduce mortality in chronic obstructive pulmonary disease

Salmeterol and fluticasone propionate did not reduce mortality in chronic obstructive pulmonary disease Salmeterol and fluticasone propionate did not reduce mortality in chronic obstructive pulmonary disease | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Salmeterol and fluticasone propionate did not reduce mortality in chronic obstructive pulmonary disease Article Text Therapeutics Salmeterol and fluticasone propionate did

2008 Evidence-Based Medicine

64. Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder inhaler in asthma patients (Abstract)

Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder inhaler in asthma patients The adjustable-dose budesonide/formoterol dry powder inhaler (DPI) has demonstrated similar or greater asthma control with less inhaled corticosteroid compared with the fixed-dose budesonide/formoterol DPI.We sought to evaluate the efficacy, tolerability, and resource use of maintenance therapy with the adjustable (...) -dose budesonide/formoterol pressurized metered-dose inhaler versus the fixed-dose budesonide/formoterol pressurized metered-dose inhaler and the fixed-dose fluticasone propionate/salmeterol DPI.This was a randomized, open-label, multicenter study of patients (N = 1225) 12 years and older with moderate-to-severe persistent asthma. After 10 to 14 days of current therapy, patients were randomized 2:1 to fixed-dose budesonide/formoterol (160/4.5 microg x 2 inhalations [320/9 microg] twice daily

2008 EvidenceUpdates Controlled trial quality: uncertain

65. Comparison of the anti-inflammatory effects of extra-fine hydrofluoroalkane-beclomethasone vs fluticasone dry powder inhaler on exhaled inflammatory markers in childhood asthma (Abstract)

Comparison of the anti-inflammatory effects of extra-fine hydrofluoroalkane-beclomethasone vs fluticasone dry powder inhaler on exhaled inflammatory markers in childhood asthma Extra-fine hydrofluoroalkane-beclomethasone differs from other inhaled corticosteroids by its fine aerosol characteristics. Therefore, extra-fine hydrofluoroalkane-beclomethasone may be particularly useful for treating peripheral airway inflammation in asthma.To analyze the anti-inflammatory effects of extra-fine (...) hydrofluoroalkane-beclomethasone vs fluticasone dry powder inhaler (DPI) in asthmatic children by measuring bronchial and alveolar nitric oxide (NO) and inflammatory markers in exhaled breath condensate (EBC).In a 6-month crossover study, 33 children aged 6 to 12 years with moderate persistent asthma were randomly treated with extra-fine hydrofluoroalkane-beclomethasone (200 microg daily via an Autohaler) and fluticasone DPI (200 microg daily via a Diskus). The primary outcome variables were alveolar

2008 EvidenceUpdates Controlled trial quality: uncertain

66. Effect of once-daily fluticasone furoate nasal spray on nasal symptoms in adults and adolescents with perennial allergic rhinitis (Abstract)

Effect of once-daily fluticasone furoate nasal spray on nasal symptoms in adults and adolescents with perennial allergic rhinitis Intranasal corticosteroids are recommended as first-line therapy for the treatment of allergic rhinitis. Fluticasone furoate is a novel enhanced-affinity glucocorticoid for the treatment of allergic rhinitis.To compare the efficacy and safety of intranasal fluticasone furoate with those of vehicle placebo nasal spray in adult and adolescent patients with perennial (...) allergic rhinitis (PAR).After screening (7-14 days), patients 12 years and older with confirmed PAR were randomized to receive fluticasone furoate, 110 microg once daily, or placebo once daily intranasally for 4 weeks in this double-blind, multicenter study. The primary end point was mean change from baseline during the entire treatment period in daily reflective total nasal symptom score (rTNSS), recorded on diary cards by patients, using a 4-point categorical scale.The mean reduction from baseline

2008 EvidenceUpdates Controlled trial quality: predicted high

67. Veramyst (fluticasone furoate)

Veramyst (fluticasone furoate) Drug Approval Package: Veramyst (fluticasone furoate) NDA #022051 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Veramyst (fluticasone furoate) Company: GlaxoSmithKline NDA: 022051 Approval Date: 4/27/2007 (PDF) (PDF) Medical Review(s) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Administrative Document(s) and Correspondence (PDF) (PDF) (PDF) (PDF) Date created: November 3, 2008 Updated: July 16, 2012 Note

2007 FDA - Drug Approval Package

68. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. Full Text available with Trip Pro

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. Long-acting beta-agonists and inhaled corticosteroids are used to treat chronic obstructive pulmonary disease (COPD), but their effect on survival is unknown.We conducted a randomized, double-blind trial comparing salmeterol at a dose of 50 microg plus fluticasone propionate at a dose of 500 microg twice daily (combination regimen), administered with a single inhaler, with placebo, salmeterol alone (...) , or fluticasone propionate alone for a period of 3 years. The primary outcome was death from any cause for the comparison between the combination regimen and placebo; the frequency of exacerbations, health status, and spirometric values were also assessed.Of 6112 patients in the efficacy population, 875 died within 3 years after the start of the study treatment. All-cause mortality rates were 12.6% in the combination-therapy group, 15.2% in the placebo group, 13.5% in the salmeterol group, and 16.0

2007 NEJM Controlled trial quality: predicted high

69. Combination therapy with the single inhaler salmeterol/fluticasone propionate versus increased doses of inhaled corticosteroids in patients with asthma

Combination therapy with the single inhaler salmeterol/fluticasone propionate versus increased doses of inhaled corticosteroids in patients with asthma Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 DARE.

70. Cost-effectiveness of salmeterol xinafoate/fluticasone propionate combination inhaler in chronic asthma

Cost-effectiveness of salmeterol xinafoate/fluticasone propionate combination inhaler in chronic asthma Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 NHS Economic Evaluation Database.

71. Secondary prevention of asthma by the use of Inhaled Fluticasone propionate in Wheezy INfants (IFWIN): double-blind, randomised, controlled study. (Abstract)

Secondary prevention of asthma by the use of Inhaled Fluticasone propionate in Wheezy INfants (IFWIN): double-blind, randomised, controlled study. Wheezing and asthma often begins in early childhood, but it is difficult to predict whether or not a wheezy infant will develop asthma. Some researchers suggest that treatment with inhaled corticosteroids at the first signs of wheezing in childhood could prevent the development of asthma later in life. However, other investigators have reported (...) that although such treatment could help control symptoms, the benefits can disappear within months of stopping treatment. We tested our hypothesis that to prevent loss of lung function and worsening asthma later in childhood, anti-inflammatory treatment needs to be started early in life.We did a randomised, double-blind, controlled study of inhaled fluticasone propionate 100 mug twice daily in young children who were followed prospectively and randomised after either one prolonged (>1 month) or two

2006 Lancet Controlled trial quality: predicted high

72. Inhaled ciclesonide versus inhaled budesonide or inhaled beclomethasone or inhaled fluticasone for chronic asthma in adults: a systematic review

Inhaled ciclesonide versus inhaled budesonide or inhaled beclomethasone or inhaled fluticasone for chronic asthma in adults: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 DARE.

73. [Sustained reduction in bronchial hyperresponsiveness within three days of inhaled fluticasone propionate in mild asthma:time course after onset and cessation of treatment]. (Abstract)

[Sustained reduction in bronchial hyperresponsiveness within three days of inhaled fluticasone propionate in mild asthma:time course after onset and cessation of treatment]. 15326966 2005 02 15 2015 11 19 0012-7183 120 13 2004 Duodecim; laaketieteellinen aikakauskirja Duodecim [Sustained reduction in bronchial hyperresponsiveness within three days of inhaled fluticasone propionate in mild asthma:time course after onset and cessation of treatment]. 1591-3 Sovijärvi Anssi R A AR HUSLAB, kliinisen (...) fysiologian ja isotooppilääketieteen laboratoriot, HUS. Haahtela Tari T Ekroos Heikki J HJ Lindqvist Ari A Saarinen Antti A Poussa Tuija T Laitinen Lauri A LA fin Clinical Trial Comparative Study Journal Article Randomized Controlled Trial Hengitettävä kortikosteroidi vähentää keuhkoputkien supistumisherkkyyttä astmassa luultua nopeammin. Finland Duodecim 0373207 0012-7183 0 Androstadienes CUT2W21N7U Fluticasone IM Administration, Inhalation Adolescent Adult Androstadienes administration & dosage Asthma

2005 Duodecim; laaketieteellinen aikakauskirja Controlled trial quality: uncertain

74. Effect of fluticasone propionate and salmeterol in a single device, fluticasone propionate, and montelukast on overall asthma control, exacerbations, and costs

Effect of fluticasone propionate and salmeterol in a single device, fluticasone propionate, and montelukast on overall asthma control, exacerbations, and costs Effect of fluticasone propionate and salmeterol in a single device, fluticasone propionate, and montelukast on overall asthma control, exacerbations, and costs Effect of fluticasone propionate and salmeterol in a single device, fluticasone propionate, and montelukast on overall asthma control, exacerbations, and costs O'Connor R D (...) , Stanford R, Crim C, Yancey S W, Edwards L, Rickard K A, Dorinsky P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of three alternative first-line maintenance treatments for asthma control: fluticasone propionate (100 microg

2004 NHS Economic Evaluation Database.

75. Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma

Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma O'Connor R D, Nelson H, Borker R, Emmett A, Jhingran P (...) , Rickard K, Dorinsky P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Two combination treatments for patients with persistent asthma were examined. One was fluticasone propionate (FP) 100 microg and salmeterol (SAL) 50 microg

2004 NHS Economic Evaluation Database.

76. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. Full Text available with Trip Pro

Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. To explore the efficacy and safety of fluticasone propionate, cream and ointment, applied twice weekly in addition to maintenance treatment with emollients, in reducing the risk of relapse of chronic recurrent atopic dermatitis.Randomised, double blind, parallel group study of 20 weeks' duration.Dermatology outpatient (...) clinics (6 countries, 39 centres).Adult (aged 12-65) patients with moderate to severe atopic dermatitis who were experiencing a flare.Participants applied fluticasone propionate (0.05% cream or 0.005% ointment; once or twice daily) regularly for four weeks to stabilise their condition. The patients whose disease was brought under control then continued into a 16 week maintenance phase, applying emollient on a daily basis with a bath oil as needed and either the same formulation of fluticasone

2003 BMJ Controlled trial quality: predicted high

77. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. (Abstract)

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Inhaled long-acting beta2 agonists improve lung function and health status in symptomatic chronic obstructive pulmonary disease (COPD), whereas inhaled corticosteroids reduce the frequency of acute episodes of symptom exacerbation and delay deterioration in health status. We postulated that a combination of these treatments would be better than each component used alone (...) .1465 patients with COPD were recruited from outpatient departments in 25 countries. They were treated in a randomised, double-blind, parallel-group, placebo-controlled study with either 50 microg salmeterol twice daily (n=372), 500 microg fluticasone twice daily (n=374), 50 microg salmeterol and 500 microg fluticasone twice daily (n=358), or placebo (n=361) for 12 months. The primary outcome was the pretreatment forced expiratory volume in 1s (FEV1) after 12 months treatment' and after patients had

2003 Lancet Controlled trial quality: predicted high

78. Cost-effectiveness of fluticasone propionate in the treatment of chronic obstructive pulmonary disease: a double-blind randomized, placebo-controlled trial

Cost-effectiveness of fluticasone propionate in the treatment of chronic obstructive pulmonary disease: a double-blind randomized, placebo-controlled trial Cost-effectiveness of fluticasone propionate in the treatment of chronic obstructive pulmonary disease: a double-blind randomized, placebo-controlled trial Cost-effectiveness of fluticasone propionate in the treatment of chronic obstructive pulmonary disease: a double-blind randomized, placebo-controlled trial Ayres J G, Price M J, Efthimiou (...) J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of fluticasone propionate (FP; 2 puffs of 250 microg twice daily), added to regular bronchodilator therapy for the treatment of chronic obstructive pulmonary disease

2003 NHS Economic Evaluation Database.

79. Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial. Full Text available with Trip Pro

Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial. To assess the effect of montelukast versus salmeterol added to inhaled fluticasone propionate on asthma exacerbation in patients whose symptoms are inadequately controlled with fluticasone alone. Design and setting A 52 week, two period, double blind, multicentre trial during which patients whose symptoms remained (...) uncontrolled by inhaled corticosteroids were randomised to add montelukast or salmeterol.Patients (15-72 years; n = 1490) had a clinical history of chronic asthma for > or = 1 year, a baseline forced expiratory volume in one second (FEV1) value 50-90% predicted, and a beta agonist improvement of > or = 12% in FEV1.The primary end point was the percentage of patients with at least one asthma exacerbation.20.1% of the patients in the group receiving montelukast and fluticasone had an asthma exacerbation

2003 BMJ Controlled trial quality: predicted high

80. Use of salmeterol/fluticasone combination (seretide) in an asthma clinic: a pragmatic open study from primary care

Use of salmeterol/fluticasone combination (seretide) in an asthma clinic: a pragmatic open study from primary care Use of salmeterol/fluticasone combination (seretide) in an asthma clinic: a pragmatic open study from primary care Use of salmeterol/fluticasone combination (seretide) in an asthma clinic: a pragmatic open study from primary care Clark C E Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains (...) a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of a salmeterol-fluticasone combination (Seretide) inhaler for treating asthma. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients with asthma who attended a nurse-run asthma clinic in a rural dispensing general practice. Patients

2003 NHS Economic Evaluation Database.